相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
R. T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2015)
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Raymond T. Bartus et al.
MOLECULAR THERAPY (2014)
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease
Jeffrey H. Kordower et al.
BRAIN (2013)
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
Christopher D. Herzog et al.
NEUROBIOLOGY OF DISEASE (2013)
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus et al.
NEUROLOGY (2013)
α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Mickael Decressac et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Open-Label Surgical Trials for Parkinson Disease: Time for Reconsideration
Ron L. Alterman et al.
ANNALS OF NEUROLOGY (2011)
Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
Raymond T. Bartus et al.
MOVEMENT DISORDERS (2011)
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease
Raymond T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2011)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
Xiaomin Su et al.
HUMAN GENE THERAPY (2009)
Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy
Chee Yeun Chung et al.
JOURNAL OF NEUROSCIENCE (2009)
Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity
Fredric P. Manfredsson et al.
MOLECULAR THERAPY (2009)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum
Christopher D. Herzog et al.
MOLECULAR THERAPY (2008)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi et al.
MOLECULAR THERAPY (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
分享论文
